These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 25802198)

  • 21. Primary antiphospholipid syndrome-associated diffuse alveolar hemorrhage.
    Cartin-Ceba R; Peikert T; Ashrani A; Keogh K; Wylam ME; Ytterberg S; Specks U
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):301-10. PubMed ID: 23983016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The use of recombinant activated factor VII for blood loss after cardiovascular surgery].
    Gong ZY; Gao CQ; Xiao CS; Li BJ; Ma XH; Zhang CM
    Zhonghua Wai Ke Za Zhi; 2008 Oct; 46(19):1497-501. PubMed ID: 19094631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy of recombinant activated factor VII in diffuse alveolar haemorrhage].
    Dabar G; Harmouche C; Jammal M
    Rev Mal Respir; 2011 Jan; 28(1):106-11. PubMed ID: 21277485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant activated factor VII in patients with acute liver failure with UNOS Status 1A: a single tertiary academic centre experience.
    Pham HP; Hsu SX; Parker-Jones S; Samstein B; Diuguid D; Schwartz J
    Vox Sang; 2014 Jan; 106(1):75-82. PubMed ID: 23815226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant activated factor VII use in the emergency department.
    Fishman PE; Drumheller BC; Dubon ME; Slesinger TL
    Emerg Med J; 2008 Oct; 25(10):625-30. PubMed ID: 18843055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery.
    Chapman AJ; Blount AL; Davis AT; Hooker RL
    Eur J Cardiothorac Surg; 2011 Dec; 40(6):1314-8; discussion 1318-9. PubMed ID: 21601468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact on postoperative bleeding and cost of recombinant activated factor VII in patients undergoing heart transplantation.
    Hollis AL; Lowery AV; Pajoumand M; Pham SM; Slejko JF; Tanaka KA; Mazzeffi M
    Ann Card Anaesth; 2016; 19(3):418-24. PubMed ID: 27397445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of life-threatening hemorrhages and unsafe interventions in nonhemophiliac children by recombinant factor VIIa.
    Leblebisatan G; Sasmaz I; Antmen B; Yildizdas D; Kilinc Y
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):77-82. PubMed ID: 18838398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antineutrophil cytoplasmic antibody-associated vasculitis complicated with diffuse alveolar hemorrhage: a study of 12 cases.
    Lin Y; Zheng W; Tian X; Zhang X; Zhang F; Dong Y
    J Clin Rheumatol; 2009 Oct; 15(7):341-4. PubMed ID: 20009969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of recombinant activated factor VII (rFVIIa) in the management of patients with major haemorrhage in military hospitals over the last 5 years.
    Smith JE
    Emerg Med J; 2013 Apr; 30(4):316-9. PubMed ID: 22609697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A clinical analysis of 32 patients with diffuse alveolar hemorrhage in diffuse connective tissue diseases].
    Chen GX; Dong Y; Ju ZB
    Zhonghua Nei Ke Za Zhi; 2008 May; 47(5):362-5. PubMed ID: 18953941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diffuse alveolar hemorrhage in systemic lupus erythematosus: risk factors and clinical outcome: results from affiliated hospitals of Catholic University of Korea.
    Kwok SK; Moon SJ; Ju JH; Park KS; Kim WU; Cho CS; Kim HY; Park SH
    Lupus; 2011 Jan; 20(1):102-7. PubMed ID: 20956464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune diffuse alveolar hemorrhage: Clinical presentation and outcome.
    Quadrelli S; Dubinsky D; Solis M; Yucra D; Hernández M; Karlen H; Brigante A
    Respir Med; 2017 Aug; 129():59-62. PubMed ID: 28732837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diffuse alveolar hemorrhage.
    Newsome BR; Morales JE
    South Med J; 2011 Apr; 104(4):269-74. PubMed ID: 21606695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of recombinant activated factor VII in the treatment of massive pulmonary hemorrhage in a preterm infant.
    Cetin H; Yalaz M; Akisu M; Karapinar DY; Kavakli K; Kultursay N
    Blood Coagul Fibrinolysis; 2006 Apr; 17(3):213-6. PubMed ID: 16575260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factor viia for alveolar hemorrhage in microscopic polyangiitis.
    Betensley AD; Yankaskas JR
    Am J Respir Crit Care Med; 2002 Nov; 166(9):1291-2. PubMed ID: 12403702
    [No Abstract]   [Full Text] [Related]  

  • 37. Usefulness of laboratory values in predicting effectiveness of recombinant factor VIIa in surgical patients with bleeding.
    Gruber SN; Volles DF
    Am J Health Syst Pharm; 2013 Sep; 70(17):1528-32. PubMed ID: 23943185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increasing incidence of diffuse alveolar hemorrhage following allogeneic bone marrow transplantation: cryptic etiology and uncertain therapy.
    Lewis ID; DeFor T; Weisdorf DJ
    Bone Marrow Transplant; 2000 Sep; 26(5):539-43. PubMed ID: 11019844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases.
    Mitsiakos G; Papaioannou G; Giougi E; Karagianni P; Garipidou V; Nikolaidis N
    J Pediatr Hematol Oncol; 2007 Mar; 29(3):145-50. PubMed ID: 17356391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting response to rFVIIa in neonates with intractable bleeding or severe coagulation disturbances.
    Gkiougki E; Mitsiakos G; Chatziioannidis E; Papadakis E; Nikolaidis N
    J Pediatr Hematol Oncol; 2013 Apr; 35(3):221-6. PubMed ID: 23511491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.